BIO-RAD LABORATORIES -CL B (BIO.B)
US0905721082 - Common Stock
Taking everything into account, BIO.B scores 4 out of 10 in our fundamental rating. BIO.B was compared to 58 industry peers in the Life Sciences Tools & Services industry. BIO.B is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. BIO.B has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year BIO.B was profitable.
In the past year BIO.B had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: BIO.B reported negative net income in multiple years.
Each year in the past 5 years BIO.B had a positive operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of -5.18%, BIO.B is in line with its industry, outperforming 54.24% of the companies in the same industry.
BIO.B has a Return On Equity (-7.29%) which is comparable to the rest of the industry.
BIO.B has a Return On Invested Capital of 2.48%. This is in the better half of the industry: BIO.B outperforms 69.49% of its industry peers.
BIO.B had an Average Return On Invested Capital over the past 3 years of 2.68%. This is significantly below the industry average of 9.89%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -5.18% | ||
| ROE | -7.29% | ||
| ROIC | 2.48% |
ROA(3y)-2.72%
ROA(5y)8.64%
ROE(3y)-4.64%
ROE(5y)11.05%
ROIC(3y)2.68%
ROIC(5y)2.71%
1.3 Margins
Looking at the Operating Margin, with a value of 13.82%, BIO.B is in the better half of the industry, outperforming 74.58% of the companies in the same industry.
BIO.B's Operating Margin has improved in the last couple of years.
With a decent Gross Margin value of 53.57%, BIO.B is doing good in the industry, outperforming 62.71% of the companies in the same industry.
In the last couple of years the Gross Margin of BIO.B has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 13.82% | ||
| PM (TTM) | N/A | ||
| GM | 53.57% |
OM growth 3Y-6.13%
OM growth 5Y9.94%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.75%
GM growth 5Y-0.04%
2. Health
2.1 Basic Checks
BIO.B has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
Compared to 1 year ago, BIO.B has less shares outstanding
The number of shares outstanding for BIO.B has been reduced compared to 5 years ago.
The debt/assets ratio for BIO.B is higher compared to a year ago.
2.2 Solvency
An Altman-Z score of 3.20 indicates that BIO.B is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 3.20, BIO.B is in the better half of the industry, outperforming 62.71% of the companies in the same industry.
The Debt to FCF ratio of BIO.B is 5.50, which is a neutral value as it means it would take BIO.B, 5.50 years of fcf income to pay off all of its debts.
BIO.B's Debt to FCF ratio of 5.50 is fine compared to the rest of the industry. BIO.B outperforms 69.49% of its industry peers.
A Debt/Equity ratio of 0.14 indicates that BIO.B is not too dependend on debt financing.
BIO.B has a Debt to Equity ratio (0.14) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.14 | ||
| Debt/FCF | 5.5 | ||
| Altman-Z | 3.2 |
ROIC/WACC0.21
WACC11.85%
2.3 Liquidity
A Current Ratio of 5.83 indicates that BIO.B has no problem at all paying its short term obligations.
With a decent Current ratio value of 5.83, BIO.B is doing good in the industry, outperforming 76.27% of the companies in the same industry.
A Quick Ratio of 4.34 indicates that BIO.B has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 4.34, BIO.B is in the better half of the industry, outperforming 71.19% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.83 | ||
| Quick Ratio | 4.34 |
3. Growth
3.1 Past
The earnings per share for BIO.B have decreased strongly by -17.29% in the last year.
The Earnings Per Share has been growing by 15.01% on average over the past years. This is quite good.
Looking at the last year, BIO.B shows a decrease in Revenue. The Revenue has decreased by -4.68% in the last year.
The Revenue has been growing slightly by 3.13% on average over the past years.
EPS 1Y (TTM)-17.29%
EPS 3Y3.78%
EPS 5Y15.01%
EPS growth Q2Q-6.34%
Revenue 1Y (TTM)-4.68%
Revenue growth 3Y1.62%
Revenue growth 5Y3.13%
Revenue growth Q2Q-6.73%
3.2 Future
The Earnings Per Share is expected to grow by 6.32% on average over the next years.
The Revenue is expected to grow by 3.40% on average over the next years.
EPS Next Y-8.2%
EPS Next 2Y2.13%
EPS Next 3Y6.32%
EPS Next 5YN/A
Revenue Next Year0.7%
Revenue Next 2Y2.99%
Revenue Next 3Y3.4%
Revenue Next 5YN/A
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 23.78 indicates a rather expensive valuation of BIO.B.
Based on the Price/Earnings ratio, BIO.B is valued cheaply inside the industry as 84.75% of the companies are valued more expensively.
The average S&P500 Price/Earnings ratio is at 28.06. BIO.B is around the same levels.
BIO.B is valuated quite expensively with a Price/Forward Earnings ratio of 25.91.
Compared to the rest of the industry, the Price/Forward Earnings ratio of BIO.B indicates a rather cheap valuation: BIO.B is cheaper than 81.36% of the companies listed in the same industry.
BIO.B is valuated rather expensively when we compare the Price/Forward Earnings ratio to 20.72, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 23.78 | ||
| Fwd PE | 25.91 |
4.2 Price Multiples
Based on the Price/Free Cash Flow ratio, BIO.B is valued a bit cheaper than 69.49% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 43.1 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)1.58
EPS Next 2Y2.13%
EPS Next 3Y6.32%
5. Dividend
5.1 Amount
No dividends for BIO.B!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
BIO-RAD LABORATORIES -CL B
NYSE:BIO.B (4/18/2024, 7:04:00 PM)
279.91
-58.64 (-17.32%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap9.41B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 23.78 | ||
| Fwd PE | 25.91 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)1.58
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -5.18% | ||
| ROE | -7.29% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 13.82% | ||
| PM (TTM) | N/A | ||
| GM | 53.57% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.22
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.14 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 5.83 | ||
| Quick Ratio | 4.34 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-17.29%
EPS 3Y3.78%
EPS 5Y
EPS growth Q2Q
EPS Next Y-8.2%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-4.68%
Revenue growth 3Y1.62%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y